TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The  company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin and those receiving Lomustine… Berubicin’s performance in an initial safety trial conducted by another company in 2006 resulted in apparent life extension for some patients and complete remission for one patient who, unusually, survives nearly 17 years later. The ongoing study now seeks to demonstrate overall survivability of GBM patients using Berubicin, established by a decrease in the size of the tumor, arrested development of the tumor’s size once the patient is put on study, and / or a favorable change in the time to progression of the tumors,” a recent article reads. “Although data are still early, we are pleased with these results in terms of recruiting a balanced patient population to compare Berubicin to Lomustine in the treatment of GBM, which may highlight Berubicin’s potential to provide a better therapeutic option for patients after first-line therapy for their disease,” CNS Pharmaceuticals CEO John Climaco is quoted saying.

To view the full article, visit https://ibn.fm/FL1dO

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork.

Alex Pearon

Share
Published by
Alex Pearon
Breaks Categories: Stock Spotlights

Recent Posts

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Secures Roles in Two U.S. Army Microgrid Projects Valued at $144.6 Million

AZIO AI Holdings (NASDAQ: AZIO), a developer of power infrastructure for artificial intelligence ("AI") campuses,…

2 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Surpasses C$20 Million in Contracted Revenue Backlog Across Global Operations

ZenaTech (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) announced that its consolidated contracted revenue backlog has…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Signs Agreement to Support $144.6 Million in U.S. Army Microgrid Contracts

AZIO AI Holdings (NASDAQ: AZIO) announced it has signed a general contracting agreement with Energy…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Establishes Space and Government Power Team to Pursue Lunar and Defense Infrastructure Opportunities

AZIO AI Holdings (NASDAQ: AZIO) announced the formation of a dedicated space and government power…

4 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Secures Energy Sector Survey Contracts With Potential Follow-On Work Totaling Nearly C$1 Million

ZenaTech (NASDAQ: ZENA)  (FSE: 49Q) (BMV: ZENA) announced that its Drone as a Service ("DaaS")…

5 days ago